Summary of COVID-19 voxvoganan studies

1. Lütken et al., A Double-blind, Placebo-controlled, Interventional Parallel Group Study to Evaluate the Antiviral Effect of a Single Nasal Application of LTX-109 3% Gel, in Comparison to Placebo Gel, in Subjects With COVID-19 Infection.

33 patient voxvoganan early treatment RCT: 29% worse viral clearance (p=0.8).
RCT 33 patients up to 6 days from symptom onset, showing no significant difference in short-term viral load change with LTX-109.
Apr 2022, NCT04854928, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000455-39/results, https://c19p.org/lutken